ReviewAntibiotics (Basel, Switzerland)2022
Alternatives Therapeutic Approaches to Conventional Antibiotics: Advantages, Limitations and Potential Application in Medicine.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on natural products with antimicrobial potential against WHO's priority pathogens.European journal of medical research · 2025Pooled it
- NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Development of Mucoadhesive Nanofiber as an Alternate Therapeutic Regimen for Subclinical Endometritis in Cattle.Turkish journal of pharmaceutical sciences · 2026Article
- Effects of Cholesterol and Solution pH on Daptomycin-bilayer Interactions.The Journal of membrane biology · 2026Article
- Article
- Exploitation of Nanoparticle-Essential Oil Combinations to Enhance the Efficacy of Antimicrobial Agents AgainstPharmaceutics · 2026Article
- Bacteriophage cocktails and bacterial coevolution: a systematic review of resistance prevention strategies against multidrug-resistant pathogens in sewage water.Iranian journal of microbiology · 2026Article
- Deciphering microbial biofilm: mechanism, infection, and advanced approaches for control.Folia microbiologica · 2026Review
- Phytochemical investigation of Phyllanthus emblica (Amla) for therapeutic application in urinary tract infection (UTI) management and development of functional tea.Ultrasonics sonochemistry · 2026Article
- Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies.Infectious disease reports · 2026Review
- Where and when to strike: Spatiotemporally controlled smart nanomedicines for precision antibacterial therapy.Acta pharmaceutica Sinica. B · 2026Review
- Metal-antibiotic interactions: potentiometric and spectroscopic investigation of cloxacillin and dicloxacillin complexes in aqueous solution.Scientific reports · 2026Article
- Comparison of the antimicrobial, anti-biofilm, and cytotoxic effects of thymol/ampicillin and thymol/cefotaxime against Escherichia coli bacteria.BMC research notes · 2026Article
- Antibacterial and anti-biofilm activities of thyme oil, oregano oil, and their combination against Klebsiella pneumoniae and Acinetobacter baumannii polymicrobial biofilms.Antonie van Leeuwenhoek · 2026Article
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.Microorganisms · 2026Review
- Graph-based and molecular modeling approaches to identify TpiA as a noval therapeutic target in Neisseria meningitidis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cephalexin-loaded polyvinyl alcohol/graphene oxide thin films as antibacterial wound dressing.RSC advances · 2026Article
- Biosynthesis of silver nanoparticles via Melaleuca alternifolia leaf extract for antibacterial, antifungal, antioxidant and anticancer activity.Scientific reports · 2026Article
- Novel bacteriophages effectively target multidrug-resistant clinical isolates of Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Genomic characterization and biological activities of cell-free supernatant fromFrontiers in cellular and infection microbiology · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to antimicrobials and particularly multidrug resistance is one of the greatest challenges in the health system nowadays. The continual increase in the rates of antimicrobial resistance worldwide boosted by the ongoing COVID-19 pandemic poses a major public health threat. Different approaches have been employed to minimize the effect of resistance and control this threat, but the question still lingers as to their safety and efficiency. In this context, new anti-infectious approaches against multidrug resistance are being examined. Use of new antibiotics and their combination with new β-lactamase inhibitors, phage therapy, antimicrobial peptides, nanoparticles, and antisense antimicrobial therapeutics are considered as one such promising approach for overcoming bacterial resistance. In this review, we provide insights into these emerging alternative therapies that are currently being evaluated and which may be developed in the future to break the progression of antimicrobial resistance. We focus on their advantages and limitations and potential application in medicine. We further highlight the importance of the combination therapy approach, wherein two or more therapies are used in combination in order to more effectively combat infectious disease and increasing access to quality healthcare. These advances could give an alternate solution to overcome antimicrobial drug resistance. We eventually hope to provide useful information for clinicians who are seeking solutions to the problems caused by antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.